Open AccessFibroblast Growth Factor-23 and Parathyroid Hormone Are Associated with Post-Transplant Bone Mineral Density Loss
Author(s) -
Nada Kanaan,
Kathleen Claes,
JeanPierre Devogelaer,
Dirk Vanderschueren,
Geneviève Depresseux,
Éric Goffin,
Pieter Evenepoel
Publication year - 2010
Publication title -
clinical journal of the american society of nephrology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.755
H-Index - 151
eISSN - 1555-905X
pISSN - 1555-9041
DOI - 10.2215/cjn.00950110
Subject(s) - medicine , bone mineral , fibroblast growth factor 23 , parathyroid hormone , endocrinology , bone density , fibroblast growth factor , urology , osteoporosis , calcium , receptor
Among the multiple factors contributing to bone mineral density (BMD) loss after renal transplantation, hypophosphatemia is increasingly recognized to play an important role. Hypophosphatemia occurs in up to 90% of the renal transplant recipients in the early post-transplant period and is caused by renal phosphate wasting. We hypothesized that a high pretransplant level of the recently described phosphaturic hormone fibroblast growth factor 23 (FGF-23) is a risk factor for accelerated BMD loss occurring within the first post-transplant year.